sub:assertion {
sub:assertion prov:wasGeneratedBy "S&T TWOC project version 1" .
sub:version prov:value 1 .
rdf:object ns1:C0001554 "management" ;
ns1:C0220825 "investigation" ;
ns1:C0376636 "management" ;
ns1:C1261322 "investigation" ;
ns1:C1273870 "management" ;
ns1:C1521721 "supporting" ;
ns1:C1552578 "investigation" ;
ns1:C3273539 "management" ;
ns1:C5203670 "COVID-19" .
rdf:predicate ns3:TRIPLE_UID:pg3ngnxg-TRIPLE-ABSTRACT-3 "be" .
rdf:subject ns1:C0007561 "ceftriaxone" ;
ns1:C0011777 "dexamethasone" ;
ns1:C0015620 "famotidine" ;
ns1:C0052796 "azithromycin" ;
ns1:C0812732 "azithromycin" ;
ns1:C1609165 "tocilizumab" ;
ns1:C3885145 "sarilumab" .
rdfs:Triple-UID ns2:TRIPLE_UID:pg3ngnxg-TRIPLE-ABSTRACT-3 "pg3ngnxg-TRIPLE-ABSTRACT-3" .
rdfs:sentence rdfs:label "Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management." .
rdfs:triple rdfs:label "azithromycin , dexamethasone , tocilizumab , sarilumab , famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management" .
}